

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
07 November 2024 (07.11.2024)



(10) International Publication Number  
**WO 2024/228135 A1**

(51) International Patent Classification:  
*A61K 39/395* (2006.01) *C07K 16/24* (2006.01)  
*A61P 1/04* (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:  
PCT/IB2024/054245

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:  
02 May 2024 (02.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/463,658 03 May 2023 (03.05.2023) US

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: **JANSSEN BIOTECH, INC.** [US/US];  
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044  
(US).

(72) Inventors: **VETTER, Marion**; 1400 McKean Road,  
Spring House, Pennsylvania 19477 (US). **TERRY, Natalie A.**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **ROONEY, Terence**; 1400 McKean Road,  
Spring House, Pennsylvania 19477 (US). **HANS MOORE, Meredith**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **XU, Yan**; 1400 McKean Road, Spring  
House, Pennsylvania 19477 (US). **YEAGER, Barry Todd**;  
1400 McKean Road, Spring House, Pennsylvania 19477  
(US).

(74) Agent: **LANE, David A.** et al.; Johnson & Johnson, One  
Johnson & Johnson Plaza, New Brunswick, New Jersey  
08933 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: METHOD OF TREATING CROHN'S DISEASE WITH A COMBINATION OF ANTIBODIES TO IL-23 AND TNF ALPHA

(57) Abstract: A method of treating Crohn's disease (CD) by administering a combination of an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab), and a TNF- $\alpha$  inhibitor, such as an anti-TNF- $\alpha$  antibody (e.g., golimumab).

WO 2024/228135 A1